A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD

References

• Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol. 2013;28(Suppl 4):64–70.
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11:e1001680.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357.
   PubMed Web of Science ®Google Scholar
• Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2019;70:531–544.
   PubMed Web of Science ®Google Scholar
• Kaya E, Yılmaz Y. Non-alcoholic fatty liver disease: a growing public health problem in Turkey. Turk J Gastroenterol. 2019;30:865–871.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69:2672–2682.
   PubMed Web of Science ®Google Scholar
• Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323:1175–1183.
   PubMed Web of Science ®Google Scholar
• Rinella ME, Loomba R, Caldwell SH, et al. Controversies in the diagnosis and management of NAFLD and NASH. Gastroenterol Hepatol. 2014;10:219–227.
   PubMedGoogle Scholar
• Perumpail BJ, Khan MA, Yoo ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23:8263–8276.
   PubMed Web of Science ®Google Scholar
• Pais R, Barritt AS 4th, Calmus Y, et al. NAFLD and liver transplantation: current burden and expected challenges. J Hepatol. 2016;65:1245–1257.
   PubMed Web of Science ®Google Scholar
• Kaul U, Parmar D, Manjunath K, et al. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. Cardiovasc Diabetol. 2019;18:80.
   PubMed Web of Science ®Google Scholar
• Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53:362–376.
   PubMed Web of Science ®Google Scholar
• Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67:829–846.
   PubMed Web of Science ®Google Scholar
• Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999–2014.
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–209.
   PubMed Web of Science ®Google Scholar
• Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–438.
   PubMed Web of Science ®Google Scholar
• Loria P, Lonardo A, Carulli N. Should nonalcoholic fatty liver disease be renamed? Dig Dis. 2005;23:72–82.
   PubMed Web of Science ®Google Scholar
• Dufour JF. Time to abandon NASH? Hepatology. 2016;63:9–10.
   PubMed Web of Science ®Google Scholar
• Bellentani S, Tiribelli C. Is it time to change NAFLD and NASH nomenclature? Lancet Gastroenterol Hepatol. 2017;2:547–548.
   PubMed Web of Science ®Google Scholar
• Eslam M, Sanyal AJ, George J. Toward more accurate nomenclature for fatty liver diseases. Gastroenterology. 2019;157:590–593.
   PubMed Web of Science ®Google Scholar
• Fouad Y, Waked I, Bollipo S, et al. What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’. Liver Int. 2020;40:1254–1261.
   PubMed Web of Science ®Google Scholar
• Valenti L, Pelusi S. Redefining fatty liver disease classification in 2020. Liver Int. 2020;40:1016–1017.
   PubMed Web of Science ®Google Scholar
• The Lancet Gastroenterology Hepatology. Redefining non-alcoholic fatty liver disease: what’s in a name? Lancet Gastroenterol Hepatol. 2020;5:419.
   PubMed Web of Science ®Google Scholar
• Zheng KI, Fan JG, Shi JP, et al. From NAFLD to MAFLD: a “redefining” moment for fatty liver disease. Chin Med J (Engl). 2020. DOI:https://doi.org/10.1097/CM9.0000000000000981
   Google Scholar
• Araújo AR, Rosso N, Bedogni G, et al. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: what we need in the future. Liver Int. 2018;38(Suppl 1):47–51.
   PubMed Web of Science ®Google Scholar
• Boyd KM. Disease, illness, sickness, health, healing and wholeness: exploring some elusive concepts. Med Humanit. 2000;26:9–17.
   PubMedGoogle Scholar
• Cook N, Geier A, Schmid A, et al. The patient perspectives on future therapeutic options in NASH and patient needs. Front Med (Lausanne). 2019;6:61.
   PubMed Web of Science ®Google Scholar
• Cao G, Yi T, Liu Q, et al. Alcohol consumption and risk of fatty liver disease: a meta-analysis. PeerJ. 2016;4:e2633.
   PubMed Web of Science ®Google Scholar
• Hajifathalian K, Torabi Sagvand B, McCullough AJ. Effect of alcohol consumption on survival in nonalcoholic fatty liver disease: a national prospective cohort study. Hepatology. 2019;70:511–521.
   PubMed Web of Science ®Google Scholar
• Long MT, Massaro JM, Hoffmann U, et al. Alcohol use is associated with hepatic steatosis among persons with presumed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2020;18:1831–1841.
   PubMed Web of Science ®Google Scholar
• Chang Y, Cho YK, Kim Y, et al. Non-heavy drinking and worsening of non-invasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study. Hepatology. 2019;69:64–75.
   PubMed Web of Science ®Google Scholar
• GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018;392:1015–1035.
   PubMed Web of Science ®Google Scholar
• Liu B, Balkwill A, Reeves G, et al. Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. BMJ. 2010;340:c912.
   PubMed Web of Science ®Google Scholar
• Hart CL, Morrison DS, Batty GD, et al. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ. 2010;340:c1240.
   PubMedGoogle Scholar
• European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402.
   PubMed Web of Science ®Google Scholar
• Bertot LC, Jeffrey GP, Wallace M, et al. Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma. Hepatol Commun. 2017;1:53–60.
   PubMed Web of Science ®Google Scholar
• Tilg H, Effenberger M. From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol. 2020;17:387–388.
   PubMed Web of Science ®Google Scholar
• Manson JE, Skerrett PJ, Greenland P, et al. The escalating pandemics of obesity and sedentary lifestyle. A call to action for clinicians. Arch Intern Med. 2004;164:249–258.
   PubMed Web of Science ®Google Scholar
• Diehl AM, Farpour-Lambert NJ, Zhao L, et al. Why we need to curb the emerging worldwide epidemic of nonalcoholic fatty liver disease. Nat Metab. 2019;1:1027–1029.
   PubMedGoogle Scholar
• Pennisi G, Celsa C, Spatola F, et al. Pharmacological therapy of non-alcoholic fatty liver disease: what drugs are available now and future perspectives. Int J Environ Res Public Health. 2019;16:4334.
   Web of Science ®Google Scholar
• Sumida Y, Okanoue T, Nakajima A, et al. Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. Hepatol Res. 2019;49:1256–1262.
   PubMed Web of Science ®Google Scholar
• Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69:1691–1705.
   Web of Science ®Google Scholar
• Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47−64.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965.
   PubMed Web of Science ®Google Scholar
• Siddiqui MS, Van Natta ML, Connelly MA, et al. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. J Hepatol. 2020;72:25–33.
   PubMed Web of Science ®Google Scholar
• Labenz C, Prochaska JH, Huber Y, et al. Cardiovascular risk categories in patients with nonalcoholic fatty liver disease and the role of low-density lipoprotein cholesterol. Hepatol Commun. 2019;3:1472–1481.
   PubMed Web of Science ®Google Scholar
• MacEwan JP, Seabury S, Aigbogun MS, et al. Pharmaceutical innovation in the treatment of schizophrenia and mental disorders compared with other diseases. Innov Clin Neurosci. 2016;13:17–25.
   PubMedGoogle Scholar
• Younossi ZM, Rinella ME, Sanyal A, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology. 2020 Jun 16. DOI: https://doi.org/10.1002/hep.31420.
   PubMed Web of Science ®Google Scholar
• Bianco C, Romeo S, Petta S, et al. MAFLD vs NAFLD: let the contest begin! Liver Int. 2020;40:2079–2081.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Makhlouf HR. Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children. Clin Liver Dis. 2016;20:293–312.
   PubMed Web of Science ®Google Scholar
• Brown GT, Kleiner DE. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism. 2016;65:1080–1086.
   PubMed Web of Science ®Google Scholar
• Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397.
   PubMed Web of Science ®Google Scholar
• Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67:1265–1273.
   PubMed Web of Science ®Google Scholar
• Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut. 2020;69:1877–1884.
   Web of Science ®Google Scholar
• Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol. 2015;62:S65–75.
   PubMed Web of Science ®Google Scholar
• Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158:1611–1625.
   PubMed Web of Science ®Google Scholar
• Katsarou A, Moustakas II, Pyrina I, et al. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease. World J Gastroenterol. 2020;26:1993–2011.
   PubMed Web of Science ®Google Scholar
• Cheah MC, McCullough AJ, Goh GB. Current modalities of fibrosis assessment in non-alcoholic fatty liver disease. J Clin Transl Hepatol. 2017;5:261–271.
   PubMed Web of Science ®Google Scholar
• Zuberbuhler F, Boursier J. Noninvasive diagnosis of liver fibrosis in NAFLD: tips tricks. Clin Res Hepatol Gastroenterol. 2019;43:658–662.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; and International association for the study of obesity. Circulation. 2009;120:1640–1645.
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer JR, Li L, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology. 2020;71:808–819.
   PubMed Web of Science ®Google Scholar
• Benyamin B, Sørensen TIA, Schousboe K, et al. Are there common genetic and environmental factors behind the endophenotypes associated with the metabolic syndrome? Diabetologia. 2007;50:1880–1888.
   PubMed Web of Science ®Google Scholar
• Pang Z, Zhang D, Li S, et al. Multivariate modelling of endophenotypes associated with the metabolic syndrome in Chinese twins. Diabetologia. 2010;53:2554–2561.
   PubMed Web of Science ®Google Scholar
• Guloksuz S, van Os J. Renaming schizophrenia: 5 × 5. Epidemiol Psychiatr Sci. 2019;28:254–257.
   PubMedGoogle Scholar
• Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020. DOI:https://doi.org/10.1007/s12072-020-10094-2
   Google Scholar
• Mendez-Sanchez N, Arrese M, Gadano A, et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2020. DOI: https://doi.org/10.1016/S2468-1253(20)30340-X. S2468-1253(20)30340-X.
   Google Scholar
• Shiha G, Alswat K, Al Khatry M, et al. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Lancet Gastroenterol Hepatol. 2020. DOI: https://doi.org/10.1016/S2468-1253(20)30213-2. S2468-1253(20)30213-2.
   Google Scholar
• Demirtas CO, Yilmaz Y. Metabolic-associated fatty liver disease: time to integrate ground-breaking new terminology to our clinical practice? Hepatol Forum. 2020;3:79–81.
   Google Scholar
• Shiha G, Korenjak M, Eskridge W, et al. Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol. 2020. DOI: https://doi.org/10.1016/S2468-1253(20)30294-6. S2468-1253(20)30294-6.
   Google Scholar
• Fouad Y, Elwakil R, Elsahhar M, et al. The NAFLD-MAFLD debate: eminence versus evidence. Liver Int. 2020. DOI:https://doi.org/10.1111/liv.14739
   Google Scholar
• Lin S, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40:2082–2089.
   PubMed Web of Science ®Google Scholar
• Wong VW, Wong GL, Woo J, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol. 2020. S1542-3565:31504–4.
   Web of Science ®Google Scholar
• Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;40:3018–3030.
   PubMed Web of Science ®Google Scholar